Act Advisors, Llc. Acurx Pharmaceuticals, Inc. Transaction History
Act Advisors, Llc.
- $181 Million
- Q4 2024
A detailed history of Act Advisors, Llc. transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Act Advisors, Llc. holds 21,284 shares of ACXP stock, worth $16,601. This represents 0.01% of its overall portfolio holdings.
Number of Shares
21,284Holding current value
$16,601% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ACXP
# of Institutions
31Shares Held
1.42MCall Options Held
13.6KPut Options Held
4K-
Vanguard Group Inc Valley Forge, PA529KShares$412,8920.0% of portfolio
-
Prospect Financial Services LLC Melville, NY329KShares$256,6790.15% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$114,2700.0% of portfolio
-
Morgan Stanley New York, NY106KShares$82,8360.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA48.4KShares$37,7310.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $9.01M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...